Literature DB >> 29801904

Assessing mobility and balance in Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay population: Validity and reliability of four outcome measures.

Isabelle Lessard1, Bernard Brais2, Isabelle Côté3, Caroline Lavoie3, Matthis Synofzik4, Jean Mathieu3, Cynthia Gagnon5.   

Abstract

OBJECTIVE: To assess the construct validity of the 10-Meter Walk Test (10mWT), Six-Minute Walk Test (6MWT), Berg Balance Scale (BERG), and Timed Up and Go (TUG) in adults with Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS), in addition to the interrater reliability of the 10mWT and 6MWT.
METHODS: Reliability was determined using the intraclass correlation coefficient (ICC). Validity was determined first by correlating the 10mWT, 6MWT, BERG, and TUG with participant's age, lower limb coordination, and disease severity, and then by assessing their capacity to distinguish between participants based on sex and disease stages.
RESULTS: Interrater reliability of the 10mWT at both comfortable and maximum speed as well as the 6MWT is excellent (ICC = 0.97-0.99). Construct validity of the four tests was confirmed, as showed by the high correlations with age, lower limb coordination, and overall disease severity (ρ = 0.64-0.97).
CONCLUSIONS: The four tests assessed for their metrological properties in this study showed to be valid instruments to use in the ARSACS population. The 10mWT and 6MWT are also highly reliable. BERG and TUG reliability will need to be assess in a future study.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  ARSACS; Mobility; Outcome assessment (health care); Recessive ataxia; Reliability; Validity

Mesh:

Year:  2018        PMID: 29801904     DOI: 10.1016/j.jns.2018.03.033

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  5 in total

1.  Development and validation of a disease severity index for ataxia of Charlevoix-Saguenay.

Authors:  Cynthia Gagnon; Bernard Brais; Isabelle Lessard; Caroline Lavoie; Isabelle Côté; Jean Mathieu
Journal:  Neurology       Date:  2019-09-18       Impact factor: 9.910

2.  An exploratory natural history of ataxia of Charlevoix-Saguenay: A 2-year follow-up.

Authors:  Cynthia Gagnon; Isabelle Lessard; Caroline Lavoie; Isabelle Côté; Raphaël St-Gelais; Jean Mathieu; Bernard Brais
Journal:  Neurology       Date:  2018-08-29       Impact factor: 9.910

3.  From motor performance to participation: a quantitative descriptive study in adults with autosomal recessive spastic ataxia of Charlevoix-Saguenay.

Authors:  Cynthia Gagnon; Bernard Brais; Isabelle Lessard; Caroline Lavoie; Isabelle Côté; Jean Mathieu
Journal:  Orphanet J Rare Dis       Date:  2018-09-19       Impact factor: 4.123

Review 4.  Documenting manifestations and impacts of autosomal recessive spastic ataxia of Charlevoix-Saguenay to develop patient-reported outcome.

Authors:  Marjolaine Tremblay; Laura Girard-Côté; Bernard Brais; Cynthia Gagnon
Journal:  Orphanet J Rare Dis       Date:  2022-10-01       Impact factor: 4.303

5.  Docosahexaenoic acid in ARSACS: observations in two patients.

Authors:  Ivana Ricca; Alessandra Tessa; Rosanna Trovato; Giacomo Maria Bacci; Filippo Maria Santorelli
Journal:  BMC Neurol       Date:  2020-05-28       Impact factor: 2.474

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.